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Thirty-day readmission (30-DR) has become an important quality-of-care measure. Allogeneic hematopoietic
cell transplantation (allo-HCT) presents a medical setting with higher readmission rates. We analyzed factors
affecting 30-DR and its impact on patient outcomes and on health care costs in 91 patients who underwent
reduced-toxicity conditioning (RTC) allo-HCT with ﬂudarabine and busulfan. The patient cohort was divided
into 2: the readmission group (R-gp) or the no-readmission group (NR-gp). Overall, 38% (n ¼ 35) required
readmission with a median time to readmission of 14 days. In multivariate analysis, only documented
infection during the index admission predicted 30-DR, P ¼ .01. With a median follow-up of 18 months (range,
1 to 69) for surviving patients, the 2-year overall survival was 49% and 58% in the R-gp and NR-gp respec-
tively, P ¼ .48. The 1-year nonrelapse mortality in R-gp and NR-gp was 18% and 13% respectively, P ¼ .43. The
median post-transplantation hospital charges in the R-gp and NR-gp were $85,115 (range, $32,015 to
$242,519) and $45,083 (range, $10,715 to $485,456), P ¼ .0002. In conclusion, only documented infections
during the index hospitalization inﬂuenced 30-DR after RTC allo-HCT. Although 30-DR did not adversely
affect mortality or survival, it was associated with signiﬁcantly increased 100-day post-transplantation
hospital charges, thus supporting its role as a quality-of-care measure in allo-HCT patients.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Readmission to the hospital within 30 days of discharge
from a prior admission has emerged as an important topic of
discussion and debate within the medical community. Cen-
ters for Medicare and Medicaid Services (CMS) considers
30-day readmission (30-DR) as a quality-of-care indicator
and has recently implemented the Hospital Readmission
Reduction Program with proposed penalization of hospitals
with high rates of risk-adjusted readmissions [1]. Review of
the claims data of a large cohort of Medicare patients sug-
gests approximately 20% readmission rates for its beneﬁ-
ciaries and also noted that only 10% of such readmissions
were planned [2]. Published data pertaining to hospital
readmissions show signiﬁcant heterogeneity in readmission
rates based on geographical location, diagnosis, severity of
illness, and socioeconomic status [1-7]. Various strategies,
including improving transition of care, effective discharge
planning, immediate postdischarge telephone encounter,
and short-term clinic follow-up, have been identiﬁed asdgments on page 419.
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13.12.559potential measures to decrease readmissions [5,8-10].
Readmission rates alone maybe a crude gauge of quality-of-
care, as studies have shown that, although it does adversely
affect health care costs and quality of life, increased 30-DR in
heart failure patients was associated with lower 30-day
mortality, possibly because of increased use of hospital re-
sources [11-13].
Allogeneic hematopoietic cell transplantation (allo-HCT)
is a widely used therapeutic strategy in the management of
various hematologic disorders. Although potentially curative,
allo-HCT’s therapy-related morbidity is signiﬁcant, and the
readmission rates in allo-HCT patients are higher than those
of their peers, ranging from 39% to 51% [14-17]. A handful of
prior reports have shown that infections during index
admission, HCT-comorbidity index (HCT-CI), donor type,
stem cell source, and conditioning regimen may predict the
risk of readmission in allo-HCT recipients [14,15,18]. The ef-
fect of readmission on survival is more contentious, with
some reports suggesting inferior survival [14,15], whereas 1
report in the pediatric population showed better survival in
the readmission group [18]. The impact of 30-DR after allo-
HCT on health care costs is not known. In this study, we
analyzed 30-DR rates and its predictors in a cohort of patients
with hematologic malignancies who underwent reduced-
toxicity conditioning (RTC) allo-HCT. We also evaluated theTransplantation.
Table 1
Baseline Patient Characteristics
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of allo-HCT recipients.Characteristic Readmission
(n ¼ 35)
Not Readmitted
(n ¼ 56)
P
Value
Age, median (range) 56 (17-72) 54 (22-68) .23
Male 21 (60) 34 (61) .99
Diagnosis .93
ALL/AML/MDS 23 (65.7) 39 (70)
CLL/CML 2 (5.7) 3 (5)
Hodgkin/NHL/Others 10 (28.6) 14 (25)
Disease risk* .18
Low 16 (45.7) 24 (43)
Intermediate 3 (8.6) 13 (23)
High 16 (45.7) 19 (34)
Disease status .49
Chemosensitive 23 (66) 41 (73)
Refractory disease 12 (34) 15 (27)
Prior number of therapy,
median (range)
2 (1-6) 2 (0-6) .65
Prior radiation therapy 2 (6) 8 (14) .31
Prior autologous
transplantation
2 (6) 6 (11) .71
KPS, median (range) 80 (60-100) 85 (70-100) .44
HCT-CI, median (range) 2 (0-7) 1 (0-5) .31
Busulfan dose .12
High 27 (77) 34 (61)
Low 8 (23) 22 (39)
Patients receiving
thymoglobulin
23 (66) 31 (55) .38
Donor type
Unrelated 19 (54) 28 (50) .83
Matched sibling 16 (46) 28 (50)
HLA mismatchy .99MATERIALS AND METHODS
Patient Population
Ninety-four consecutive patients underwent peripheral blood allo-HCT
after RTC with ﬂudarabine/busulfan between August 2007 and December
2012 at our transplantation center. Three patients who died before discharge
from the index transplantation admission were excluded. The remaining
91 patients are the subjects of this report. The cohort was divided into 2
groups based on whether they were readmitted within 30 days of discharge
after index transplantation admission: the readmission group (R-gp, n ¼ 35)
and the no readmission group (NR-gp, n ¼ 56). The conditioning regimen
consisted of intravenous ﬂudarabine (total dose, 150 to 160 mg/m2) and
busulfan (total dose, 6.4 mg/Kg or 12.8 mg/Kg) with or without thymoglo-
bulin (total dose, 6.0 mg/Kg). High-resolution HLA typing was done at the
allele level for class-I (HLA - A, - B, - C) and class II (HLA-DRB1) molecules as
described previously [19]. Graft-versus-host-disease (GVHD) prophylaxes
included a calcineurin inhibitor (tacrolimus or cyclosporine) combined with
either mycophenolate mofetil or short-course methotrexate [20]. As stan-
dard institutional practice, patients received antibacterial, antiviral (acyclovir
or valacyclovir), and anti-fungal (ﬂuconazole) prophylaxis.
All patients were admitted to the bone marrow transplantation service
for the conditioning regimen and allograft infusion, and they remained
inpatient (IP) until neutrophil recovery and resolution of early complica-
tions. After discharge, patients were monitored daily by the bone marrow
outpatient service until dayþ100. Data pertaining to patient demographics,
disease- and transplantation-related parameters, and patient outcomes are
prospectively maintained by the dedicated transplantation data manager at
our center. Readmission and hospital charges were retrospectively obtained
from department of decision support. The study was approved by the
institutional review board and protocol review and monitoring committee
at our institution.Allele level 1 (2) 3 (5)
Antigen level 1 (2) 1 (2)
Infused CD34 cell dosez,
median (range)
6.5 (2.7-12.8) 6.5 (1.8-15.1) .98
Infused CD3 cell dosex,
median (range)
31.3 (9.6-58.5) 32.4 (11.5-94.5) .48
GVHD prophylaxis .83
MTX þ calcineurine inhibitor 22 (63) 33 (59)
MMF þ calcineurine inhibitor 13 (37) 23 (41)
Caregiver .13
Spouse 17 (49) 37 (66)
Other 18 (51) 19 (34)
Number of caregivers .99
1 30 (86) 47 (84)
2þ 5 (14) 9 (16)
Documented unreliable
caregiver
3 (9) 5 (9) .99
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia;
MDS, myelodysplastic syndrome; CLL, chronic lymphoblastic leukemia;
CML, chronic myeloid leukemia; NHL, non-Hodgkin lymphoma; KPS, Kar-
nofsky performance status; HCT-CI, hematopoietic cell transplantation-
comorbidity index; ATG, antithymocyte globulin; HLA, human leukocyteStudy Deﬁnitions
Thirty-day readmission was deﬁned as any patient who required inpa-
tient admission within 30 days of discharge from the index transplantation
admission for any reason. The primary objective was to evaluate the factors
predicting 30-DR in patients undergoing RTC allo-HCT. The lists of variables
utilized in our analysis are shown in Tables 1 and 2 and include patient-,
disease-, and transplantation-related factors and caregiver support avail-
able. The hospital charges up to day þ100 after transplantation incurred
after discharge from index transplantation admission in the 2 groups were
collected and analyzed to identify the effect of readmission on health care
costs. The impact of 30-DR on progression free survival (PFS), overall sur-
vival (OS), relapse rate (RR), and nonrelapse morality (NRM) was evaluated.
Neutrophil recovery was deﬁned as ﬁrst of 3 consecutive days to an absolute
neutrophil count (ANC)  .5 x 109/L, after post-transplantation nadir and
platelet recovery as ﬁrst of 7 consecutive days to platelet count  20 x 109/L
without platelet transfusion. OS was deﬁned as the time to death from any
cause from the date of transplantation. Death and relapse/progression were
considered events for PFS. Surviving patients were censored at time of last
follow-up. NRM was deﬁned as death from any cause other than disease
progression or relapse.antigen; GVHD, graft versus host disease; MTX, methotrexate; MMF,
mycophenolate mofetil.
Data presented are n (%) unless otherwise indicated.
* American Society for Blood and Marrow Transplantation: standard
criteria [26].
y High-resolution HLA typing at the allele level for A, B, C, and DRB-1 for
all patients.
z Cell dose x 106/kg patient body weight.
x Cell dose x 107/kg patient body weight.Statistical Analysis
Descriptive statistics were used to summarize patient characteristics.
Categorical data were described using contingency tables including counts
and percentages. Continuously scaled measures were summarized with
descriptive statistical measures (ie, mean [ SD] or median [range]). Fisher’s
exact test and Wilcoxon’s rank-sum test were used to compare categorical
and continuous variables, respectively. The univariate and multivariable
logistic regression models were used to assess the risk factors for read-
mission. Survival curves were estimated using the Kaplan-Meier method
and survival between readmission groups was compared using a 2-sided
log-rank test. The cumulative incidences of NRM and RR were estimated
by considering these 2 events as competing risks [21]. Cox proportional
hazards model was constructed for potential variables predicting 30-DR,
using a limited backward selection procedure. Variables considered in the
model were those signiﬁcant at a ¼ .20 level from the univariable model.
Variables remaining in the ﬁnal model were signiﬁcant at a ¼ .05 level.
Estimates for hazard ratios and corresponding 95% conﬁdence intervals (CI)
were obtained for each signiﬁcant prognostic factor. All P values are 2 sided.
Statistical analyses were carried out using SAS 8.2, SPLUS, version 2000
(Insightful Corp., Seattle, WA) and R statistical software (Foundation for
Statistical Computing, Vienna, Austria).RESULTS
Patient Characteristics
The baseline characteristics of the patient cohort (n ¼ 91)
are shown in Table 1. All patients received T cellereplete,
unmanipulated, peripheral blood allografts after RTC with
ﬂudarabine/busulfan from matched sibling (n ¼ 44) or un-
related (n ¼ 47) donors, P ¼ .83. There were no differences
between the R-gp and NR-gp with regards to age, gender,
race, and caregiver status. The proportion of refractory
Table 3
Univariate Analysis of Risk Factors for Readmissions
Risk Factor Odds Ratio* (95% CI) P Value
Age (per 10-year increments) 1.01 (.97-1.05) .54
Gender .97 (.41-2.30) .95
Diagnosis (acute leukemia/MDS versus
others)
.84 (.34-2.06) .70
Disease risk
Low - -
Intermediate .35 (.09-1.41) .08
High 1.26 (.50-3.16) .12
Disease status (chemosensitive versus
refractory)
.70 (.28-1.75) .45
Prior number of therapy 1.01 (.67-1.52) .95
Table 2
Post-transplantation Outcomes
Outcome Readmission
(n ¼ 35)
Not Readmitted
(n ¼ 56)
P
Value
Neutrophil recovery*, median
(range)
14.5 (5-27) 17 (5-23) .09
Platelet recoveryy, median
(range)
13 (7-44) 12 (7-19) .21
Acute GVHD, time to onset,
median (range), d
40.5 (14-279) 45 (12-137) .97
Acute GVHD, grade II-IV 11 (31) 12 (21) .11
Length of stay for index
admission, median (range), d
25 (20-38) 26 (14-73) .68
Documented infection during
index admission, n (%)
14 (40) 11 (20) .05
Time to readmission, median
(range), d
14 (1-29) NA
Time to readmission
 7 days, n (%) 8 (23) NA
> 7 but  30 days, n (%) 27 (77) NA
Cause of readmissionz, n (%)
Documented infection 12 (31.6) NA
Fever without documented
infection
6 (15.8) NA
Cardiovascular 6 (15.8) NA
Respiratory 4 (10.5) NA
Gastrointestinal 4 (10.5) NA
GVHD 3 (7.9) NA
Otherx 3 (7.9) NA
Greater than 1 cause of
readmission, n (%)
3 (9) NA
Length of readmission stay,
median (range), d
3 (1-34) NA
Follow-up surviving patients,
median (range), d
480 (71-2005) 532 (31-2080)
GVHD indicates graft-versus-host disease; PFS, progression-free survival.
* Deﬁned as absolute neutrophil count (ANC) > 500 x 3 days.
y Deﬁned as platelets > 20 x 7 days without transfusion support.
z Three patients were readmitted for multiple reasons, all causes were
included.
x Includes neurologic, genitourinary, and musculoskeletal complications.
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15) respectively, P ¼ .49. No difference was noted in the
number of prior therapies, including previous radiation or
autografting between the groups (P > .1).Prior radiation therapy .36 (.07-1.82) .22
Prior autologous transplantation .51 (.10-2.66) .42
KPS .98 (.93-1.03) .37
HCT-CI 1.22 (.97-1.53) .10
High busulfan dose (high versus low) 2.18 (.84-5.67) .11
GVHD prophylaxis (MMF versus MTX) .85 (.36-2.02) .71
Pretransplantation ATG 1.55 (.65-3.71) .33
Donor type (sibling versus unrelated) .84 (.36-1.96) .69
HLA mismatch 3.0 (.08-107.45) .55
Infused CD34 cell dose .97 (.85-1.12) .69
Infused CD3 cell dose .98 (.95-1.02) .30
Days to neutrophil recovery .95 (.84-1.08) .41
Days to platelet recovery 1.11 (.97-1.26) .13
Acute GVHD, median days to onset
(range)
1.00 (.99-1.02) .81
Severity of acute GVHD (< grade II
versus ‡ grade II)
1.68 (.65-4.38) .29
Length of stay for index admission .99 (.93-1.05) .78
Infection during index admission 2.72 (1.06-7.01) .04
Caregiver (spouse versus other) .49 (.21-1.15) .10
Number of caregivers (1 versus > 1) 1.15 (.35-3.76) .82
CI indicates conﬁdence interval; MDS, myelodysplastic syndrome; KPS,
Karnofsky performance status; ATG, antithymocyte globulin; HCT-CI,
hematopoietic cell transplantationecomorbidity index; MMF, mycopheno-
late mofetil; MTX, methotrexate; HLA, human leukocyte antigen; GVHD,
graft-versus-host disease.
* Odds ratio of greater than 1 implies risk factor more in the readmission
group compared to nonreadmission group.Thirty-day Readmissions
A total of 35 patients (38%) were readmitted within 30
days of discharge after index transplantation admission, with
a median time to readmission of 14 days (range, 1 to 29)
(Table 2). Documented infection (n ¼ 12) was the leading
cause of readmission followed by cardio-pulmonary compli-
cations (n ¼ 10), fever without a documented infection (n ¼
6), gastrointestinal issues (n ¼ 4), and GVHD (n ¼ 3). Docu-
mented infections leading to readmissions included central
lineeassociated bloodstream infections (n ¼ 4), BK-virus
hemorrhagic cystitis (n ¼ 3), Clostridium difﬁcile colitis (n ¼
2), and 1 case each of bacterial urinary tract infection, viral
pneumonitis, and cytomegalovirus reactivation. The median
length of stay after readmission was 3 days (range, 1 to 34).
Eight (23%) of the 35 readmission occurred within a week of
index discharge. Themain causes for early readmissions were
fever (n ¼ 3) and cardio-pulmonary complications (n ¼ 3).
We analyzed the data to identify risk factors that may
predict 30-DR after initial discharge. The variables used and
the results of the univariate analysis are shown in Table 3.
Social factors, such as the type of primary caregiver (spouse
versus others) and the number of caregivers, did not affectreadmission risk. In multivariate analysis only, documented
infections during index admission predicted 30-DR, (40%
versus 20%; odds ratio, 5.24; 95% CI, 1.42 to 19.32; P ¼ .01). A
proportional hazards regression analysis was performed to
identify risk factors for documented infections during the
initial hospital stay. None of the variables tested, including
use of antithymocyte globulin in the conditioning regimen,
were found to be signiﬁcantly associated with infections
during index transplantation stay (P > .05) (Supplementary
Table 1S).
Mortality and Survival
Themedian follow-up for surviving patients for the entire
cohort was 521 days (range, 31 to 2080). At last follow-up,
51.4% (n ¼ 18) in the R-gp and 60.7% (n ¼ 34) in the NR-gp
were alive. The estimated 1-year and 2-year OS in the R-gp
and NR-gp were 58% and 67% and 49% and 58%, respectively
(Figure 1); log-rank P value ¼ .48. The 1-year PFS was 50%
and 50.3% in the R-gp and NR-gp, respectively; P ¼ .8
(Figure 2). The 100-day NRM was 0% and 3.5% in R-gp and
NR-gp respectively (P ¼ .43) and the corresponding 1-year
NRM and RR were 18% and 13% (P ¼ .43) and 32% and 37%
(P ¼ .79), respectively (Figure 3).
Health Care Costs
Data for health care cost analysis was extracted from
electronic medical records and billing up to 100 days after
Figure 1. Kaplan-Meier estimates of overall survival (OS) in the readmission
group (R-gp) and no-readmission group (NR-gp), P ¼ .48 by log-rank test.
Figure 3. Cumulative incidence curves of non-relapse mortality (NRM) and
relapse rate (RR) in the readmission group (R-gp) and no-readmission group
(NR-gp).
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during the index admission (Table 4). Limited information
pertaining to outpatient (OP) costs was available before 2008
because of an institution-wide change in billing record-
keeping. OP hospital charges were not available for 3 patients
in R-gp and 5 patients in NR-gp. One patient was excluded
from the NR-gp cost analysis, as the patient was discharged
from the index admission on hospice and no additional in-
formationwas available. Themean IP charges in the R-gp and
NR-gp were $45,982 (range, $5997 to $210,669) and $24,292
(range, 0 to $442,248), respectively; P < .0001. The OP
charges did not differ between the 2 groups, P ¼ .22. The
mean post-transplantation 100-day total hospital charges
incurred by the R-gp and NR-gp were $93,925 (range,
$32,015 to $242,519) and $69,143 (range, $10,715 to
$485,456), respectively; P ¼ .0002.DISCUSSION
In this study, we evaluated the rates and predictors of
30-DR in patients undergoing RTC allo-HCT, as well as its
effect on survival and health care costs, and we make several
observations. First, readmission rates even after RTC allo-HCTFigure 2. Kaplan-Meier estimates of progression-free survival (PFS) in the
readmission group (R-gp) and no-readmission group (NR-gp), P ¼ .8 by log-
rank test.are high (38%). Second, documented infections during index
hospitalization are strong predictors of 30-DR; hence, iden-
tifying a patient population of interest, for future quality
improvement efforts. Third, with limitations of our sample
size in mind, 30-DR did not appear to impact OS, PFS, RR,
or NRM after transplantation. Fourth (and most notably),
30-DR was signiﬁcantly associated with increased post-
transplantation health care costs, justifying its place as a
quality-of-care measure in allo-HCT population.
As lawmakers and health care professionals aim to
improve the quality of health care in the United States, the
implementation of all-cause 30-DR as an index of poor
quality-of-care has sparked widespread debate. It may be
erroneous to hold patients with different diagnoses and
treatment plans to the same standards. As recently reported
in abstract form, readmission rates among oncology patients
were found to be approximately 32% higher than those of
their peers with other disease conditions. Among those,
patients with hematological malignancies and those under-
going HCT had a signiﬁcantly higher readmission rate (46%)
[16]. Our study, speciﬁc to allo-HCT patients, had a 30-DR of
38% and is comparable to other single-institution reports
[14,15,17]. This is in stark contrast to reports of autologous
HCT that show readmission rates of 14% and exempliﬁes the
limitation of instituting the same quality-of-care model for
different treatment protocols and programs [22].
Allogeneic HCT recipients constitute a unique cohort of
patients with signiﬁcantly higher risk of cytopenias, GVHD,
prolonged immunosuppression, and infections, including
those associated with central venous catheters. Bejanyan
et al., in their report of allo-HCT after myeloablative condi-
tioning, found documented infections, higher HCT-CI, and
total body irradiation (TBI)econditioning as risk factors for
increased 30-DR [14]. In contrast, our report evaluated pa-
tients receiving peripheral blood HCT after lower intensity
and/or toxicity conditioning with ﬂudarabine/busulfan and
found only documented infections as a predictor for 30-DR.
This difference between the studies is likely explained by
higher therapy-related morbidity associated with ablative
conditioning with TBI in high-risk patients, which leads to
increased readmissions. Dungarwalla et al., in their abstract,
reported readmissions by dayþ100 (as opposed to 30-DR) in
reduced-intensity conditioning allo-HCT and found no pre-
dictors for rehospitalizations, but they noted infections as
Table 4
Hospital Charges
Hospital Charges* Readmission Not Readmitted P Value
n Median/Mean (range) n Median/Mean (range)
Inpatient charges 32 25,698.73/45,982.41 (5,997.15-210,669.08) 54 0/24,292.30 (0-442,248.04) <.0001
Outpatient charges 32 43,280.43/47,942.85 (0-118,513.37) 50 37,834.77/42,421.10 (10,714.78-82,711.17) .22
Total charges 32 85,115.45/93,925.26 (32,014.86-242,519.35) 50 45,083.09/69,142.63 (10,714.78-485,456.08) .0002
* Includes only post-transplantation charges after discharge from index admission and up to day þ100. All charges in US dollars.
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did not affect the NRM, RR, PFS, or OS. In the Bejanyan
study, 30-DR increased the risk of all-causemortality, leading
to inferior OS. This variance is probably explained by the fact
that in their study, the 2 predictive factors for readmission,
ablative conditioning with TBI and higher HCT-CI, may have
negatively inﬂuenced survival [23,24]. It is also possible that
the relatively small sample size in our study prevented
detection of a signiﬁcant difference in OS and NRM.
Health care cost is increasingly becoming a major deter-
minant in health care policy. The inﬂuence of 30-DR on
hospital costs after HCT has not been previously reported, to
our knowledge. In our study, 30-DR signiﬁcantly increased
the post-transplantation IP hospital charges as well the
overall 100-day post-transplantation charges. It may be
noted that the OP charges were similar in both groups. The
signiﬁcantly escalated IP cost found in our analysis provides
support to using 30-DR as a quality-of-care parameter in
patients undergoing allo-HCT. It is, however, important to
point out that our analysis utilized hospital charges, and it
may not be reﬂective of charges at other centers. Also, these
charges are not identical to actual institutional reimburse-
ment. We decided to estimate cost on hospital charges, in
order to circumvent large reimbursement variations across
various payers (CMS, Medicaid, private insurance, self pay,
etc.) and variations across state lines. In October 2012, CMS
implemented a plan to reduce Medicare payments for
Inpatient Prospective Payment System for hospitals with
excess readmissions. Excess readmissions are measured as a
ratio, by dividing a hospital’s number of “predicted” 30-DR
for heart attack, heart failure, and pneumonia by the num-
ber that would be “expected,” based on an average hospital
with similar patients. A ratio greater than 1 indicates excess
readmissions. However, it remains unclear how and if this
metric would, in the future, be applicable to the HCT popu-
lation [25].
In our institution, the HCT program has an elaborate and
well-organized discharge process. Discharge planning is
instituted at least 5 days before the planned day of release, all
medications are reconciled, and printed copies of medication
lists are provided. Caregivers undergo formal discharge
training classes by the transplantation coordinators. All pa-
tients residing more than 30 minutes from the cancer center
are discharged to an apartment complex physically attached
to the hospital buildingwith a 24-hour caregiver. They follow
up daily in the OP infusion center and are seen by a health
care professional at least 1 to 2 times a week until day þ100.
Most well-established centers have similar infrastructure for
intensive post-discharge follow-up. Under such circum-
stances, it may be argued that the high 30-DR in allograft
patients is due to the inherent risks associated with the
procedure itself and does not necessarily reﬂect poor plan-
ning or lack of appropriate follow-up. However, studies like
ours will help further identify high-risk patients; for
example, those with documented infection during index staywho may beneﬁt from closer outpatient follow-up (eg, every
other day midlevel provider visit), predischarge infectious
disease consultation, etc. Among our patients with 30-DR,
4 were admitted because of central line-associated blood-
stream infections and 2 because of C. difﬁcile colitis. It is
possible that meticulous line care, early removal of central
venous catheters, and proper hand washing precautions
could have prevented some of these readmissions. A possible
adverse consequence of penalizing hospitals in such cases is
delayed discharge from index admission, which will likely
have deleterious effects on health care costs. In our analysis,
readmissions did increase the health care costs signiﬁcantly,
thus placing substantial ﬁnancial burden on the health care
system. Policies to minimize readmissions are perhaps war-
ranted. The importance of utilizing a risk-adapted approach,
taking into consideration relevant patient and treatment-
related factors, in appraising quality-of-care utilizing 30-DR
as an indicator cannot be over emphasized [14].
Notwithstanding its retrospective nature and sample size,
this single-institution study evaluated readmission rates and
factors in peripheral blood allograft after RTC with ﬂudar-
abine/busulfan. Our readmission rates are similar to other
reports, but failed to show a signiﬁcant adverse effect of
30-DR on mortality and survival. Noting the ﬁnancial burden
caused by readmissions, its utilization as quality-of-care
indicator is justiﬁed. Although efforts to minimize read-
missions are necessary, it must be remembered that in
complex health care situations such as allo-HCT, all read-
missions are not avoidable.
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